|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Daiichi_Sankyo,_Inc.
|
|
gptkbp:acquisition
|
gptkb:Tetra_Logic_Pharmaceuticals
Kirin Holdings Company
Pro Strakan Group
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:ceo
|
gptkb:Masashi_Miyamoto
|
|
gptkbp:clinical_trial
|
ongoing
completed
phases I, II, III
|
|
gptkbp:collaborations
|
gptkb:Osaka_University
gptkb:Harvard_University
gptkb:Stanford_University
gptkb:University_of_Tokyo
gptkb:Kyoto_University
|
|
gptkbp:community_engagement
|
active
|
|
gptkbp:employees
|
approximately 5,000
|
|
gptkbp:financial_performance
|
published
|
|
gptkbp:founded
|
gptkb:1949
|
|
gptkbp:global_presence
|
over 20 countries
|
|
gptkbp:headquarters
|
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Kyowa Kirin
|
|
gptkbp:industry
|
gptkb:Company
biopharmaceuticals
|
|
gptkbp:invention
|
numerous
|
|
gptkbp:investment
|
gptkb:stock_market_index
|
|
gptkbp:partnership
|
gptkb:temple
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:philanthropy
|
active
|
|
gptkbp:products
|
gptkb:Lonsurf
gptkb:Crysvita
gptkb:Braftovi
gptkb:Kisqali
gptkb:Ninlaro
monoclonal antibodies
biopharmaceuticals
therapeutics
diagnostics
|
|
gptkbp:research_focus
|
neurology
oncology
rare diseases
immunology
|
|
gptkbp:revenue
|
$1.5 billion (2020)
|
|
gptkbp:stock_exchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:subsidiary
|
gptkb:Kyowa_Hakko_Bio_Co.,_Ltd.
|
|
gptkbp:sustainability_initiatives
|
active
|
|
gptkbp:symbol
|
4151
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
www.kyowakirin.com
|